Next-Gen Precision Drug Discovery
SyntheX is expanding the frontier of drug discovery with target-centric cell-based functional selection.
The vast majority of human proteins have been historically inaccessible as drug targets
Only 15% of the proteome consists of protein classes that are considered druggable. Approximately 70% of FDA approved drugs fall within this subset, mainly consisting of enzymes, GPCRs, and ion channels. To expand beyond those protein classes & to reach better drivers of disease, we need to exploit novel mechanisms of action that modulate protein levels or their interactions.
Additionally, existing methods focused on in-vitro binding assays or computational modeling struggle to recapitulate the complexity of a cell and capture proteins in their native environments.
SyntheX engineers cells using its ToRFLEx platform to find rare and selective drugs that modulate challenging protein targets and can exploit novel mechanisms of action.
Unleashing the Power of Synthetic Biology for Precision Drug Discovery
We engineer cells to carry out drug discovery for challenging protein targets and complex mechanisms of action. ToRFLEx isn’t just enabling faster, better, and cheaper drug discovery – but also accessing novel pharmacology and mechanisms of action.
